[go: up one dir, main page]

MX9801410A - Nuevas n-aminoalquilfluorencarboxamidas; una nueva clase de ligandos especificos del subtipo del receptor de la dopamina. - Google Patents

Nuevas n-aminoalquilfluorencarboxamidas; una nueva clase de ligandos especificos del subtipo del receptor de la dopamina.

Info

Publication number
MX9801410A
MX9801410A MX9801410A MX9801410A MX9801410A MX 9801410 A MX9801410 A MX 9801410A MX 9801410 A MX9801410 A MX 9801410A MX 9801410 A MX9801410 A MX 9801410A MX 9801410 A MX9801410 A MX 9801410A
Authority
MX
Mexico
Prior art keywords
aminoalkylfluorenecarboxamides
novel
new class
dopamine receptor
receptor subtype
Prior art date
Application number
MX9801410A
Other languages
English (en)
Inventor
Yuanjun
Xi Chen
Original Assignee
Neurogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corp filed Critical Neurogen Corp
Publication of MX9801410A publication Critical patent/MX9801410A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Se describen los compuestos de la formula (I) o las sales farmacéuticamente aceptables de los mismos, en donde: G representa un grupo de la formula (a), (b) o (c) en donde R4 y R6 representa hidrogeno, o substituyentes orgánico; A es un alquileno opcionalmente substituidos; R1, R2, R3, R4 representan substituyentes orgánicos o inorgánicos; R5 es hidrogeno o alquilo inferior; R6 y R7 independientemente representan hidrogeno, alquilo inferior; o conjuntamente forman un anillo de 5 a 8 miembros; Z es nitrogeno o carbono; y W es arilo o heteroarilo opcionalmente substituido.
MX9801410A 1995-09-13 1996-09-12 Nuevas n-aminoalquilfluorencarboxamidas; una nueva clase de ligandos especificos del subtipo del receptor de la dopamina. MX9801410A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/527,790 US5659033A (en) 1995-09-13 1995-09-13 N-aminoalkylfluorenecarboxamides; a new class of dopamine receptor subtype specific ligands
PCT/US1996/014650 WO1997010229A1 (en) 1995-09-13 1996-09-12 Novel n-aminoalkylfluorenecarboxamides; a new class of dopamine receptor subtype specific ligands

Publications (1)

Publication Number Publication Date
MX9801410A true MX9801410A (es) 1998-05-31

Family

ID=24102933

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9801410A MX9801410A (es) 1995-09-13 1996-09-12 Nuevas n-aminoalquilfluorencarboxamidas; una nueva clase de ligandos especificos del subtipo del receptor de la dopamina.

Country Status (14)

Country Link
US (3) US5659033A (es)
EP (2) EP0873329B1 (es)
JP (1) JP2983296B2 (es)
KR (1) KR100280572B1 (es)
AT (1) ATE201867T1 (es)
AU (1) AU703350B2 (es)
CA (1) CA2231364C (es)
DE (1) DE69613240T2 (es)
ES (1) ES2159758T3 (es)
HU (1) HUP9901436A3 (es)
IL (1) IL123585A0 (es)
MX (1) MX9801410A (es)
NZ (1) NZ318653A (es)
WO (1) WO1997010229A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5659033A (en) * 1995-09-13 1997-08-19 Neurogen Corporation N-aminoalkylfluorenecarboxamides; a new class of dopamine receptor subtype specific ligands
US5763609A (en) * 1996-03-21 1998-06-09 Neurogen Corporation Certain pyrrolo pyridine-3-carboxamides; a new class of gaba brain receptor ligands
US5703083A (en) * 1996-04-15 1997-12-30 Neurogen Corporation N-aminoalkyl-1-biphenylenyl-2-carboxamides; new dopamine receptor subtype specific ligands
US5703237A (en) * 1996-04-18 1997-12-30 Neurogen Corporation N-Aminoalkyl-2-anthraquinonecarboxamides; new dopamine receptor subtype specific ligands
AU6230698A (en) * 1997-02-26 1998-09-18 Sumitomo Pharmaceuticals Company, Limited Dopamine d4 receptor antagonist
US6576643B2 (en) 1997-09-19 2003-06-10 Smithkline Beecham Corporation Vitronectin receptor antagonists
DZ2609A1 (fr) * 1997-09-19 2003-03-01 Smithkline Beecham Corp Composés nouveaux antagonistes des récepteurs de vitronectine et compositions pharmaceutiques les contenant.
CA2310250A1 (en) * 1997-11-14 1999-05-27 August Masaru Watanabe Treatment for alzheimer's disease
GB0117531D0 (en) * 2001-02-16 2001-09-12 Aventis Pharm Prod Inc Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands
CA2438318A1 (en) * 2001-02-16 2002-08-29 Aventis Pharmaceuticals Inc. Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands
ATE348099T1 (de) * 2001-02-16 2007-01-15 Aventis Pharma Inc Heterocyclische harnstoffderivate und deren verwendung als dopamine d3 receptor liganden
US20040176467A1 (en) * 2001-08-09 2004-09-09 Neil Richtand Method of preventing or reducing the occurrence of symptoms of psychosis
HUP0103987A3 (en) * 2001-09-28 2004-11-29 Richter Gedeon Vegyeszet Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
DE602008004794D1 (de) 2007-09-14 2011-03-10 Addex Pharmaceuticals Sa 1',3'-disubstituierte 4-phenyl-3,4,5,6-tetrahydro-2h,1'h-ä1,4'übipyridinyl-2'-one
EP2344470B1 (en) 2008-09-02 2013-11-06 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
CN102232074B (zh) 2008-11-28 2014-12-03 奥梅-杨森制药有限公司 作为代谢性谷氨酸盐受体调节剂的吲哚和苯并噁嗪衍生物
AR076861A1 (es) 2009-05-12 2011-07-13 Addex Pharma Sa Derivados de 1,2,4-triazolo (4,3-a)piridina y su uso como moduladores alostericos positivos de los receptores de mglur2
WO2010130422A1 (en) 2009-05-12 2010-11-18 Ortho-Mcneil-Janssen Pharmaceuticals, Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
ES2552455T3 (es) 2010-11-08 2015-11-30 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
CA2814998C (en) 2010-11-08 2019-10-29 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
PH12019500127B1 (en) 2014-01-21 2022-05-04 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
SMT201900545T1 (it) 2014-01-21 2019-11-13 Janssen Pharmaceutica Nv Combinazioni comprendenti modulatori allosterici positivi o agonisti ortosterici del recettore glutammatergico metabotropico sottotipo 2 e loro utilizzo
WO2017181004A1 (en) * 2016-04-14 2017-10-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selective d3 dopamine receptor agonists and methods of their use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2527798A (en) * 1947-08-15 1950-10-31 Searle & Co Basic fluorenyl ketones and carbinols and the production thereof
CH450398A (de) * 1964-02-18 1968-01-31 Hoffmann La Roche Verfahren zur Herstellung von Dibenzocycloheptatrienverbindungen
FR1537901A (fr) * 1967-07-19 1968-08-30 Bruneau & Cie Lab Dérivés amidés d'acides halogéno et nitro benzoïques et leur préparation
GB1279843A (en) * 1969-05-23 1972-06-28 Science Union & Cie Benzamidoethyl-piperazines and process for their preparation
FR2081559A1 (en) * 1970-03-03 1971-12-10 Cerm Cent Europ Rech Mauvernay 1-(p-chlorophenyl)-4-(3-aroylamino-butyl)-piperazines - useful as anti-histamines and spasmolytics
US4552982A (en) * 1983-08-01 1985-11-12 Eli Lilly And Company Synthesis of 9-carbamoyl-9-(3-aminopropyl)fluorenes
DK611489A (da) * 1988-12-08 1990-06-09 Duphar Int Res Anxiolytisk aktive piperazinderivater og farmaceutiske praeparater med indhold af saadanne forbindelser
FR2682953B1 (fr) * 1991-10-23 1995-04-21 Inst Nat Sante Rech Med Nouveaux derives de naphtamides, leur procede de preparation et leur application dans le domaine therapeutique.
EP0714292A4 (en) * 1993-06-23 1996-10-09 Cambridge Neuroscience Inc SIGMA RECEPTOR LIGANDS AND THEIR USE
IT1266582B1 (it) * 1993-07-30 1997-01-09 Recordati Chem Pharm Derivati (di)azacicloesanici e diazacicloeptanici
US5395835A (en) * 1994-03-24 1995-03-07 Warner-Lambert Company Naphthalamides as central nervous system agents
US5659033A (en) * 1995-09-13 1997-08-19 Neurogen Corporation N-aminoalkylfluorenecarboxamides; a new class of dopamine receptor subtype specific ligands

Also Published As

Publication number Publication date
CA2231364A1 (en) 1997-03-20
ATE201867T1 (de) 2001-06-15
WO1997010229A1 (en) 1997-03-20
JPH10511114A (ja) 1998-10-27
EP0873329B1 (en) 2001-06-06
KR19990044620A (ko) 1999-06-25
IL123585A0 (en) 1998-10-30
EP0873329A1 (en) 1998-10-28
HUP9901436A3 (en) 2000-03-28
KR100280572B1 (ko) 2001-02-01
DE69613240T2 (de) 2002-04-25
EP1081142A3 (en) 2001-10-24
NZ318653A (en) 1999-11-29
HUP9901436A2 (hu) 1999-08-30
ES2159758T3 (es) 2001-10-16
US5932734A (en) 1999-08-03
DE69613240D1 (de) 2001-07-12
US6015900A (en) 2000-01-18
CA2231364C (en) 2002-11-26
JP2983296B2 (ja) 1999-11-29
AU703350B2 (en) 1999-03-25
US5659033A (en) 1997-08-19
AU7019396A (en) 1997-04-01
EP1081142A2 (en) 2001-03-07

Similar Documents

Publication Publication Date Title
MX9801410A (es) Nuevas n-aminoalquilfluorencarboxamidas; una nueva clase de ligandos especificos del subtipo del receptor de la dopamina.
UA76409C2 (uk) Трифенілалкенові похідні і їх застосування як селективних модуляторів рецепторів естрогену
BG106073A (en) Quinoline derivatives as inhibitors of mek enzymes
ATE288895T1 (de) Wachstumshormon-freisetzende oxindolderivate
CA2401711A1 (en) Cyclic amide derivatives
MX9703736A (es) Ciertos derivados de imidazol 4-aminometil-2-sustituidos y derivados de imidazol 2-aminometil-4-sustituidos y nuevas clases de ligandos especificos para el subtipo de receptor de dopamina.
TW341565B (en) Indole derivatives processes and intermediates for their preparation and pharmaceutical compositions containing them
TW359670B (en) Process for producing quinazolin-4-one derivatives
ES469952A1 (es) Un procedimiento para la preparacion de aminoalquiltiofenos
MY108967A (en) Triazolopyridazine compounds, their production and use
MY109337A (en) Phenoxyl-and phenoxyalkyl-piperidines as antiviral agents
MY113266A (en) New indol derivatives derivatives with high affinity 5-ht1a receptor.
MY117092A (en) Chemotherapeutic pyrrolocarbazole derivatives
MY138051A (en) Compounds and processes
MY100115A (en) Nitrogen containing heterocyclic compounds, and their production and use.
MY131762A (en) Pharmaceutical compounds
ATE247660T1 (de) Furopyridinderivate und ihre therapeutische verwendung
MY109714A (en) Process for preparing 8-chloroquinolone derivatives
MY106383A (en) Process for preparing ergoline derivatives.
GB9812211D0 (en) Cinnamoyl distamycin analogous derivatives,process for their preparation,and their use as antitumor agents
HU0201262D0 (es)
CA2053705A1 (en) Piperazine derivatives
EP1197211A4 (en) CANCER PREVENTION AND TREATMENT ACTIVE INGREDIENTS
ATE21511T1 (de) Cyclische amide.
CA2245926A1 (en) 7-phenyl-1,4-diazepane compounds, process for their preparation, and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees